Ann: Dimerix presentation at Bioshares Biotech Summit, page-48

@Josh101 you are right to query this misalignment. Contrary to the assertion of the other poster, the inclusion of paediatric patients is highly unlikely to alter the recruitment trajectory to any great extent. The proportion of paediatric patients is going to be small based on evidence from the other big phase 3 FSGS trial recently completed, sparsentan DUPLEX, where less than 10% of their trial sample was paediatric patients (you can source the paper online to confirm what I am saying is true), and they ran their trial in 200 sites. DXB has nothing like that number of sites up and running and from their earlier ANN about the start of paediatric recruitment, only 15 hospitals will be recruiting paediatric patients? According to other posters, China was supposed to be DXB's banker but there is no evidence of any activity there which has to be a concern. People here will come out saying this is fear mongering, but these are the facts. At current trial performance, mid 2025 for next interim is off the table I'm sorry to say.